Cempra, Inc. to Present at RBC Capital Markets 2014 Global Healthcare Conference and Cowen 34th Annual Health Care Conference

Cempra, Inc. to Present at RBC Capital Markets 2014 Global Healthcare
Conference and Cowen 34th Annual Health Care Conference

CHAPEL HILL, N.C., Feb. 19, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc.
(Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief
executive officer of Cempra, will present at the RBC Capital Markets 2014
Global Healthcare Conference at 1:35 p.m. EST, Tuesday, Feb. 25, at The New
York Palace Hotel in New York City, and at the Cowen 34^th Annual Health Care
Conference at 1:30 p.m. EST, Monday, March 3, at The Boston Marriott Copley
Place in Boston. Dr. Fernandes will discuss the company's two differentiated
antibiotics, solithromycin (CEM-101) for community-acquired bacterial
pneumonia and TAKSTA (CEM-102 or fusidic acid) for the chronic, oral treatment
of Gram-positive pathogens including methicillin-resistant S. aureus (MRSA) in
prosthetic joint infections.

A live webcast of the presentation at the RBC Capital Markets 2014 Global
Healthcare Conference will be available on Cempra's website at www.cempra.com.
The presentation will be archived on the company's website and available for
90 days.

About Cempra, Inc.

Founded in 2006, Cempra, Inc. is a late clinical-stage pharmaceutical company
focused on developing antibiotics to treat critical bacterial infections in
patients in both acute and primary care settings. Cempra's two lead product
candidates are currently in advanced clinical development. Solithromycin
(CEM-101) is in two Phase 3 clinical trials for community-acquired bacterial
pneumonia (CABP) and is licensed to strategic commercial partner Toyama
Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain
exclusive rights in Japan. TAKSTA™ (CEM-102) is Cempra's second product
candidate currently in a Phase 2 clinical trial for prosthetic joint
infections. TAKSTA was recently granted orphan drug designation for this
indication. Both product candidates seek to address the need for new
treatments targeting drug-resistant bacterial infections in the hospital and
in the community. The company also intends to use its series of proprietary
lead compounds from its novel macrolide library for uses such as the treatment
of chronic inflammatory diseases, endocrine diseases and gastric motility
disorders. Additional information about Cempra can be found at www.cempra.com.

Please Note: This press release contains forward-looking statements regarding
future events. These statements are just predictions and are subject to risks
and uncertainties that could cause actual events or results to differ
materially. These risks and uncertainties include, among others: the results,
timing, costs and regulatory review of our studies and clinical trials; the
results of studies of our product candidates conducted by others; our ability
to obtain FDA approval of our product candidates; our dependence on the
success of solithromycin and Taksta; our need to obtain additional funding and
our ability to obtain future funding on acceptable terms; our anticipated
capital expenditures and our estimates regarding our capital requirements; the
possible impairment of, or inability to obtain, intellectual property rights
and the costs of obtaining such rights from third parties; and innovation by
our competitors. The reader is referred to the documents that we file from
time to time with the Securities and Exchange Commission.

CONTACT: Investor and Media Contacts:
         Robert E. Flamm, Ph.D.
         Russo Partners, LLC
         (212) 845-4226
         Robert.flamm@russopartnersllc.com
        
         Andreas Marathovouniotis
         Russo Partners, LLC
         (212) 845-4235
         Andreas.marathis@russopartnersllc.com
 
Press spacebar to pause and continue. Press esc to stop.